MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Work
Year: 2020
Type: article
Abstract: To explore a prognostic or predictive role of MRI and O-(2-18F-fluoroethyl)-L-tyrosine (18FET) PET parameters for outcome in the randomized multicenter trial ARTE that compared bevacizumab plus radiot... more
Source: Clinical Cancer Research
Authors Hans‐Georg Wirsching, Ulrich Roelcke, Jonathan Weller, Thomas Hundsberger, Andreas F. Hottinger +8 more
Institutions University Hospital of Zurich, University of Zurich, Kantonsspital Aarau, University of St. Gallen, Spital Thurgau (Switzerland) +4 more
Cites: 49
Cited by: 24
Related to: 10
FWCI: 2.627
Citation percentile (by year/subfield): 74.81
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze
Funder F. Hoffmann-La Roche